



ANKARA ONCOLOGY
CLINICAL RESEARCH
CENTER



**ANKARA ONCOLOGY TRAINING AND
RESEARCH HOSPITAL
CLINICAL RESEARCH CENTER & PHASE I
CLINICAL RESEARCH CENTER**



ANKARA ONCOLOGY
CLINICAL RESEARCH
CENTER





ANKARA ONCOLOGY HOSPITAL TRAINING AND RESEARCH HOSPITAL



- Ankara Oncology Hospital is an academic comprehensive cancer center in Turkey.
- We take care of over 1 million patients per year.
- There are 10,000 new cancer diagnoses.
- There is a university hospital that provides education in 24 departments or divisions and serves a total of 42 specialties.
- It has the largest medical oncology and hematology clinics in Turkey.
- It has a center that performs all types of stem cell transplants, including over 100 autologous, allogeneic, cord blood, and haploidentical transplants per year, and we have performed over 2,000 stem cell transplants to date.





Prof. Dr. Fevzi ALTUNTAŞ

Director, Clinical Research Center




Fevzi Altuntas

Professor of Medicine, Ankara Yıldırım Beyazıt University
ybu.edu.tr üzerinde doğrulanmış e-posta adresine sahip - [Ana Sayfa](#)

Hematology Bone Marrow Transplantation Leukemia Lymphoma Myeloma

MAKALELER ALINTI YAPANLAR KATKIDA BULUNAN YAZARLAR

	Hepsi	2018 yılından bugüne
Citations	4202	2839
H index	29	20
I10 index	65	42



- Article:
 - Around 200 SCI/E
 - Over 60 nationally indexed journals
- Citation: Over 4500
- Poster: Around 800
- Book/Book chapter: Around 70
- H index: 30
- I10 index: 67



altuntas f Search

Advanced Create alert Create RSS User Guide

Filters Timeline Sort by: Most recent Display options

Save Email Send to

169 results Page 1 of 17

- An effective treatment in Erdheim Chester disease: vemurafenib; a case report.
1 Bozan E, Darçın T, Yaman S, Yiğenoğlu TN, Kızıl Çakar M, Dal MS, **Altuntas F**.
Cite J Med Case Rep. 2023 Oct 12;17(1):426. doi: 10.1186/s13256-023-04153-z.
PMID: 37821987 Free PMC article.
Share
- Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
2 Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samirani H, Bussell JB, Godar M, Ayguasanos J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group.
Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28.
PMID: 37778358 Clinical Trial.
Share
- Real-world data on the effectiveness and safety of ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.
3 Bakırtaş M, Dal MS, Yiğenoğlu TN, Giden AO, Serin I, Başçı S, Kalpakçı Y, Korkmaz S, Ekinçi O, Albayrak M, Basturk A, Ozatlı D, Dogu MH, Hacibekiroglu T, Çakar MK, Ulas T, Miskioglu M, Gulturk E, Eser B, **Altuntas F**.
J Chemother. 2023 Oct;35(6):563-569. doi: 10.1080/1120009X.2023.2208439. Epub 2023 May 21.
PMID: 37211906
Share
- Resveratrol prevents ovariectomy-induced bone qua

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

CLINICAL RESEARCH CENTER

JACIE inspector certifications



this is to certify that

Fevzi Altuntas

has passed the 8th Edition JACIE Inspector Exam:

Inspection Process, Techniques and Common Standards

Friday, 20 January 2023



Kim Orchard
Chair, JACIE Committee



this is to certify that

Fevzi Altuntas

has passed the 8th Edition JACIE Inspector Exam:

Collection Standards

Friday, 20 January 2023



Kim Orchard
Chair, JACIE Committee



this is to certify that

Fevzi Altuntas

has passed the 8th Edition JACIE Inspector Exam:

Clinical Standards

Friday, 20 January 2023



Kim Orchard
Chair, JACIE Committee

EBMT cellular therapy certifications



this is to certify that:

Tugce Nur Yigenoglu

*Has achieved the accreditation of the knowledge of the main topics from
the curriculum of the European Society for Blood and Marrow
Transplantation*

with 88%

The accreditation will last five years

47th Annual Meeting [Virtual Edition] - 14th March 2021



Nicolaus Kröger
EBMT PRESIDENT



This is to certify that:

Bahar Uncu Ulu

*Has achieved the accreditation of the knowledge of the main topics from
the curriculum of the EBMT*

with 84%

The accreditation will last five years

48th Annual Meeting of the EBMT - 20 March 2022



Anna Simola
EBMT PRESIDENT



January 16, 2019
February 24, 2023
January 12, 2024

• 2019-2024
**Completed Phase 1
Study:13**

• Hematology
• Oncology
• Infectious Diseases
**Running Phase 1
Study:9**

• Hematology
• Oncology
• Infectious Diseases



ANKARA ONCOLOGY HOSPITAL
**PHASE I CLINICAL RESEARCH AND CLINICAL RESEARCH
CENTER**

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Clinical Research Center and Phase I Oncology Research Center provide services in accordance with international standards and local legislation.

The Clinical Research Center has been licensed by the Turkish Medicines and Medical Devices Agency since 2017, and the Phase I Pharmaceutical Research Center has started to provide services since 2019.

ANKARA ONCOLOGY HOSPITAL
**PHASE I CLINICAL RESEARCH AND CLINICAL RESEARCH
CENTER**

Clinical studies carried out at Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Clinical Research Center and Phase I Research Center provide services with an experienced team in their field and fully equipped work areas, and the Phase I, Phase II, It is one of the leading clinical research centers in our country with Phase III and Phase IV clinical studies.



4-Bed Clinical Unit



Physician's Room

**CCTV Monitoring
for all patient
areas**




Nurse's Room

**Archive (Restricted
access)**



**Volunteer
lounge area**

**Investigational
Product Storage
Room (Restricted
access)**




Laboratory

**-Refrigerated and
Room temperature
Centrifuge
-80° C Freezer
-Biological safety
cabinet**

PHASE I CLINICAL RESEARCH CENTER



PHASE I CLINICAL RESEARCH CENTER STAFF DELEGATION SCHEMA



MEDICAL ONCOLOGY

Prof. MD: 5

Assoc. Prof. MD: 4

Specialist MD: 5

PI and Sub-I= 14

INVESTIGATORS



Clinical Pharmacology
Prof. MD: 1
Specialist MD: 1

HEMATOLOGY

Prof. MD: 3

Assoc. Prof. MD: 3

Specialist MD: 6

PI and Sub-I= 12

The team involved in Clinical Research;

- Good Clinical Practices (GCP)
- ICH-GCP (International Conference on Harmonization-Good Clinical Practice)
- IATA (Integrated Approaches to Testing and Assessment)
- EBMT certification for cellular therapy
- Site Specific Trainings

PHASE I CLINICAL TRIALS FROM THE PAST TO THE PRESENT

NEW DIAGNOSIS\RELAPSE REFRACTORY	DIAGNOSIS	PATIENT RECRUITMENT STATUS
Newly diagnosis	Autoimmune Cytopenia	RECRUITING
Advanced Stage /Metastatic	Non- Small Cell Lung Cancer	RECRUITING
Advanced Stage	Non- Small Cell Lung Cancer	RECRUITING
Low-Intermediate Risk	Crimean-Congo Hemorrhagic Fever Disease	RECRUITING
Local/Advanced /Metastatic	Solid Tumor	RECRUITING

PHASE I CLINICAL TRIALS FROM THE PAST TO THE PRESENT

NEW DIAGNOSIS\RELAPSE REFRACTORY	DIAGNOSIS	PATIENT RECRUITMENT STATUS
Advanced Stage /Metastatic	Non- Small Cell Lung Cancer	RECRUITING
Advanced Stage /Metastatic	Solid Tumor	RECRUITING
Relapsed/Refractory	Diffuse Large B Cell Lymphoma	RECRUITING
Stage II-III A	Non-small Cell Lung Cancer	RECRUITING
Metastatic	Breast Cancer	NOT YET RECRUITING

PHASE I CLINICAL TRIALS FROM THE PAST TO THE PRESENT

NEW DIAGNOSIS\RELAPSE REFRACTORY	DIAGNOSIS	PATIENT RECRUITMENT STATUS
Relapse Refractory + Newly Diagnosed	Myelofibrosis	CLOSED
Relapse Refractory	Acute Myeloid Leukemia	CLOSED
Relapse Refractory	Multiple Myeloma	CLOSED
Advanced Stage /Metastatic	Non- Small Cell Lung Cancer	CLOSED
Relapse Refractory	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma /Mantle Cell lymphoma	CLOSED
Relapse Refractory	Acute Myeloid Leukemia	CLOSED

PHASE I CLINICAL TRIALS FROM THE PAST TO THE PRESENT

NEW DIAGNOSIS\RELAPSE REFRACTORY	DIAGNOSIS	PATIENT RECRUITMENT STATUS
Advanced Stage	Solid Tumor	CLOSED
Newly diagnosis	Covid-19	CLOSED
HER2 (-)	Gastric Adenocarcinoma	CLOSED
Advanced Stage /Metastatic	Solid Tumor	CLOSED
-	Non-transfusion dependent Betathalassemia /Low Risk Myelodysplastic Syndrome	CLOSED
Advanced Stage	Solid Tumor	CLOSED

There are 12 actively ongoing phase 1 studies

PHASE I CLINICAL RESEARCH & CLINICAL RESEARCH CENTER Hematology

47 clinical studies have been conducted in the field of Hematology from 2017 to 2023.
The numerical ratio of these studies according to phase studies is:

Phase I Studies: 6

Phase II Studies: 11

Phase III Studies: 29

Phase IV Studies: 1

There are 32 clinical studies actively ongoing in 2024



The Phase I Drug Research Center has first conducted studies on beta thalassemia or myelodysplastic syndrome disease since 2020. Studies have also been conducted on diseases such as Covid-19, B Cell Malignancies, Myelofibrosis, Acute Myeloid Leukemia, and Multiple Myeloma.



PHASE I CLINICAL RESEARCH & CLINICAL RESEARCH CENTER Medical Oncology

54 studies have been conducted in the field of Medical Oncology from 2017 to 2023.
The numerical ratio of these studies according to phase studies is:

Phase I Studies: 5

Phase II Studies: 10

Phase III Studies: 38

Phase IV Studies: 1

PHASE I CLINICAL RESEARCH & CLINICAL RESEARCH CENTER Medical Oncology

There are 35 clinical studies actively ongoing in 2024



The first study was conducted at the Phase I Drug Research Center on Non-Small Cell Lung Cancer in 2021. Additionally, clinical studies, including other phase studies, have been conducted in many diagnoses such as colorectal, stomach, breast, mesothelioma, lung, biliary, prostate, liver, head-neck and ovarian cancer.


ANKARA ONCOLOGY HOSPITAL CLINICAL RESEARCH CENTER

YEAR	NUMBER OF PATIENTS INCLUDED IN CLINICAL STUDIES
2022	154
2023	162

- It is waiting to open approved 34 Phase 1-3 studies by the end of 2024.

“CAR” T Cell Trials

- Three different clinical studies (Phase I- I/II)
- Autologous (Phase I/II)
 - mRNA is used to transfer genetic material
 - BCMA-targeted second generation CAR T cell
 - Newly diagnosed MM with high risk genetic features
- Allogeneic CAR-T (Phase I/II)
 - BCMA targeted
 - Fifth generation CAR T cell
 - Refractory MM that has received at least three lines of therapy



“CAR” T Cell Trials

CAR-T treatment side effect experience

- 39 total infusions
- Autologous CAR-T (n1=3, n2=4)
 - Grade 1 CRS (fever, fatigue, muscle and joint pain, headache) was observed and responded to paracetamol
 - Grade 1 Neurotoxicity (tendency to sleep) was observed, spontaneous regression was observed.
- Allogeneic CAR-T (n=3)
 - Grade 2 anemia, grade 2 leukopenia, grade 2 neutropenia and grade 1 thrombocytopenia were observed.
 - No Grade 3-4 adverse events were observed.

REGISTRY for HEMATOLOGY RESEARCH

CANCER TYPE	2024
Diffuse Large B-cell Lymphoma	577
Follicular Lymphoma	121
Chronic Lymphocytic Leukemia	312
Chronic Myelogenous Leukemia	166
Mantle Cell Lymphoma	56
Marginal Zone Lymphoma	120
Myelodysplastic Syndrome	121
Multiple Myeloma	399
Peripheral T Cell Lymphoma	64
Immune Thrombocytopenia	126
Hodgkin Lymphoma	535
Acute Myelogenous Leukemia	262
Acute Lymphoblastic Leukemia	136
Chronic Myeloproliferative Neoplasms	338

Total Number of Patients Registered in the Database for Related Diseases: 3610

Number of patients in oncology hospital registry in 2017-2023



- Lymphoma: 8249
- Myeloma: 5910
- Leukemia: 4962
- HCT: 1890
- Others: 2099

REGISTRY for MEDICAL ONCOLOGY RESEARCH

Cancer Type	2024
Lung	1153
Brain	118
Renal	112
Melanoma	161
Liver	45
Colorectal	1007
Breast	3124
Bladder	129
Stomach	518
Ovarian	396
Pancreatic	119
Cancer Of Unknown Primary	184
Prostate	411
Sarcoma	171
Testicular	74

Total Number of Patients Registered in the Database for Related Diseases: 9154

ETHICS COMMITTEE

- University of Health Sciences, Dr. Abdurahman Yurtarlan Ankara Oncology Training and Research Hospital, Clinical Research Ethics Committee which was established with the approval of Turkish Medicines and Medical Devices Agency (TITCK) in accordance with the principles of the Regulation on Clinical Research of Drugs and Biological Products.
- The aim of the Clinical Research Ethics Committee is to protect the rights, safety and well-being of volunteers taking part in clinical research, taking into account the scientific method and the concerns of the society.
- By acting in accordance with the current Declaration of Helsinki and following national and international standards on Good Clinical Practice, the Ethics Committee ensures timely, comprehensive and independent review of the ethical aspects of the submitted studies.

ETHICS COMMITTEE

- The Member List of the Clinical Research Ethics Committee has 13 members, consisting of people working in the scientific branches listed below.

- Microbiology
- Medical Oncology
- Urology
- Pharmacology
- Radiology
- Hematology
- Patology
- Radiation oncology
- General Surgery
- Anesthesia
- Lawyer
- Teacher

- Clinical Research Ethics Committee sessions take place every 2 weeks.
- The decision process with the application to the Ethics Committee takes 2 weeks.
- It meets every week when necessary.



- Clinical research contract and budget negotiations can begin simultaneously with ethics committee applications.
- The approval process of the contract and budget takes an average of 1-2 weeks.



The Clinical Research Center Field Coordinator is primarily given the following training:

- Center and Hospital Orientation Training
- Personal Data Protection (KVK) Training
- Basic Level Oncology Training
- Basic Level Clinical Research Training
- Advanced Level Clinical Research Training
- Study Design and Study-specific protocol training
- Electronic System Information Training
- Data Entry Systems Training
- Quality Management System Training
- Clinical research Journal "Club" hours





ANKARA ONKOLOJİ EAH

04
Aralık
Saat: 10.30

"Uyarlanabilir ve Yenilikçi Araştırma Tasarımları"
**V. KLİNİK ARAŞTIRMALAR
SEMPOZYUMU**

15
Ocak
Saat: 09.00

**KLİNİK ARAŞTIRMALAR
MERKEZİ
AÇILIŞ TÖRENİ VE SEMPOZYUMU**

20
Mayıs
Saat: 14.00

**IV. Klinik Araştırmalar
Sempozyumu**
Go To Meeting uygulaması ile online toplantı olacaktır.
<https://global.gotomeeting.com/join/480284733>



13
Ekim
Saat: 08.45

**VIII. Klinik Araştırmalar
Sempozyumu**
"KLİNİK ARAŞTIRMALARDA VERİ YÖNETİMİ"



13
Ekim
Saat: 08.45

**VIII. KLİNİK
ARAŞTIRMALAR
SEMPOZYUMU**
"KLİNİK ARAŞTIRMALARDA VERİ YÖNETİMİ"



ANKARA ONKOLOJİ EAH

Tarih: 16.01.2019
Saat: 11.00

**Faz 1 Kanser
Klinik Araştırma Merkezi
Açılış Töreni**

ANKARA ONKOLOJİ EAH KURULU AKADEMİK KURULU VE ARAŞTIRMA HASTANEKİ
www.ankoloji.gov.tr



ANKARA ONKOLOJİ EAH

**ANKARA ONKOLOJİ
KLİNİK ARAŞTIRMA GÜNLERİ**
"10. YIL DÖNÜMÜ KLİNİK ARAŞTIRMALAR MERKEZİ"

20 Mayıs 2022 Saat: 09.00
Ankara Onkoloji EAH Kurul Akademi Kurul Salonu

www.ankoloji.gov.tr



Ankara Onkoloji Eğitim ve Araştırma Hastanesi

**Klinik Araştırma
Hemşireliği Sempozyumu**

Tarih: 19 ŞUBAT 2022 / ÇARŞAMBA / Saat: 09.00

Sempozyumu izlemek için:
www.pharmackit.live





FA Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevziantuntas.com

faltuntas@hotmail.com

+90 532 658 80 50

